Contrast-induced nephropathy (CIN) is a significant problem resulting from the use of iodine contrast agents in computed tomography (CT) scans and cath lab angiography. It can have a negative impact on mortality. This article outlines some of the key information on the agents themselves, possible methods of action and how to prevent and treat CIN. How to prevent kidney damage in the cath lab.
High-osmolar agents have been replaced with low-osmolar agents such as iopamidol (Isovue) to lessen the risk of contrast-induced nephropathy.
The use of automated contrast media injectors, such as the Acist CVi system shown here, helps regulate and monitor the exact amount of contrast used during interventional procedures.

Contrast-induced nephropathy (CIN) is a significant problem resulting from the use of iodine contrast agents in computed tomography (CT) scans and cath lab angiography. It can have a negative impact on mortality. This article outlines some of the key information on the agents themselves, possible methods of action and how to prevent and treat CIN.
A radial artery angiogram demonstrating perforation of the radial artery at the bifurcation with the brachial artery, with evidence of extravasation of contra

The radial artery approach is exceptionally well-suited for diagnostic angiography and, with a lower incidence of bleeding complications, is a favorable alternative for femoral percutaneous coronary intervention (PCI). The most common complications with the transradial approach are asymptomatic radial artery occlusion (3-5 percent) and radial artery perforation (less than 1 percent).

May 15, 2012 — Boston Scientific Corp. and Philips Healthcare announced a collaboration enabling Philips to sell Boston Scientific Imaging equipment in connection with its Allura Xper catheterization lab systems in territories worldwide.


Methodist DeBakey Heart and Vascular Center in Houston, Tex., has leveraged new imaging and interventional technologies to help contain and reduce costs, increase patient volume and revenues and build a reputation as a state-of-the-art heart center.

The American College of Cardiology (ACC) 2012 Scientific Session, held March 24-27 in Chicago, was the first major cardiology show this year for vendors to display their latest innovations. A couple of key trends were evident on the show floor – new technology to support trans-aortic valve replacement (TAVR) and the launch of new cardiovascular image and information systems (CVIS) to support healthcare’s adoption of proposed Stage 2 meaningful use requirements.

May 15, 2012 — Biotronik Inc., began its U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail.

 

Sorin Group at the Heart Rhythm Society (HRS) scientific sessions announced U.S. Food and Drug Administration (FDA) approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads. Designed for effective electrical performance and durability, each of the three lead series – Tilda pacing leads, Vigila defibrillation leads and Celerity left ventricular leads – include multiple sizes and features to enable physicians to match their implant preferences with individual patient needs.

 


Patients with the heart rhythm disorder atrial fibrillation (AFib) who received first-line catheter ablation treatment had a longer arrhythmia-free interval than patients receiving anti-arrhythmic drugs, the standard first-line treatment. The preliminary findings were presented during a late-breaking session at the Heart Rhythm Society (HRS) 2012 scientific sessions last week in Boston.

 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now